PharmGen Science Inc (004720) — Cash Flow-to-Debt Ratio
PharmGen Science Inc (004720) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of ₩1.91 Billion could theoretically repay 0% of its total liabilities (₩83.70 Billion) in one year. Explore 004720 long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PharmGen Science Inc Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for PharmGen Science Inc across 13 annual periods. Also explore how large is PharmGen Science Inc's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for PharmGen Science Inc (2011–2024)
Year-by-year debt coverage analysis for PharmGen Science Inc. For market capitalisation and broader financial context, see market cap of PharmGen Science Inc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | ₩2.38 Billion | ₩114.02 Billion | ▼ -58.6% |
| 2023 | 0.05x | ₩5.44 Billion | ₩107.71 Billion | ▲ +533.0% |
| 2022 | -0.01x | ₩-1.29 Billion | ₩110.28 Billion | ▼ -114.0% |
| 2021 | 0.08x | ₩7.78 Billion | ₩93.39 Billion | ▲ +61.9% |
| 2020 | 0.05x | ₩2.68 Billion | ₩51.97 Billion | ▼ -10.7% |
| 2019 | 0.06x | ₩2.52 Billion | ₩43.79 Billion | ▼ -43.5% |
| 2018 | 0.10x | ₩4.22 Billion | ₩41.35 Billion | ▼ -3.3% |
| 2017 | 0.11x | ₩1.84 Billion | ₩17.43 Billion | ▼ -62.1% |
| 2016 | 0.28x | ₩7.75 Billion | ₩27.89 Billion | ▲ +36.6% |
| 2015 | 0.20x | ₩3.62 Billion | ₩17.79 Billion | ▲ +321.3% |
| 2014 | -0.09x | ₩-2.02 Billion | ₩21.93 Billion | ▲ +66.1% |
| 2013 | -0.27x | ₩-4.20 Billion | ₩15.49 Billion | ▼ -326.3% |
| 2011 | 0.12x | ₩2.89 Billion | ₩24.13 Billion | — |